Overview Financials News + Filings Key Docs Ownership Insiders
|
| In millions, except per share items | Mar-31-23 | Jun-30-22 | Mar-31-22 | Oct-19-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K/A |
| Revenues: |
| Medical | 66.4 | 66.8 | 60.1 | 60.3 | | 52.1 | 51.5 | |
| United States | | | | 100.0 | | | | |
| France | | | | 35.1 | | | | |
| Industrial | 115.7 | 109.0 | 103.1 | 107.7 | | 127.9 | 77.8 | |
| Other | | | | | | | 36.9 | |
| Total revenues | 182.1 | 175.8 | 163.2 | 168.0 | 0.0 | 180.0 | 166.2 | 0.0 |
| Revenue growth [+] | 11.6% | -2.3% | -1.8% | | | | | |
| Medical | 10.5% | 28.2% | 16.7% | | | | | |
| Industrial | 12.2% | -14.8% | 32.5% | | | | | |
| Point in time | 1.1% | -11.6% | -3.6% | | | | | |
| Cost of goods sold | 103.0 | 96.8 | 98.8 | 97.7 | 0.0 | 100.4 | 103.7 | 0.0 |
| Gross profit | 79.1 | 79.0 | 64.4 | 70.3 | 0.0 | 79.6 | 62.5 | 0.0 |
| Gross margin | 43.4% | 44.9% | 39.5% | 41.8% | | 44.2% | 37.6% | |
| Selling, general and administrative [+] | 85.1 | 91.0 | 90.9 | 101.6 | 2.9 | 66.7 | 60.4 | 2.0 |
| General and administrative | | | | | 2.9 | | | 2.0 |
| Research and development | 7.6 | 7.4 | 7.1 | 10.3 | | 8.2 | 11.0 | |
| Other operating expenses | | | | | -3.4 | | | 86.3 |
| EBITDA [+] | 27.7 | 25.5 | 11.3 | -15.7 | | 30.1 | 14.7 | |
| EBITDA growth | 145.1% | -15.3% | -23.1% | | -100.8% | -51411.8% | | 25894093.3% |
| EBITDA margin | 15.2% | 14.5% | 6.9% | -9.3% | | 16.7% | 8.8% | |
| Depreciation and amortization | 41.3 | 44.9 | 44.9 | 25.9 | | 25.4 | 23.6 | |
| EBIT [+] | -13.6 | -19.4 | -33.6 | -41.6 | 0.5 | 4.7 | -8.9 | -88.3 |
| EBIT growth | -59.5% | -512.8% | 277.5% | | -100.8% | -8112.1% | | 25894093.3% |
| EBIT margin | -7.5% | -11.0% | -20.6% | -24.8% | | 2.6% | -5.4% | |
| Non-recurring items [+] | | 55.2 | | | | | | |
| Asset impairment | | 55.2 | | | | | | |
| Interest income, net [+] | | | | | 0.0 | | | 0.0 |
| Interest expense | | | | 40.3 | | 32.7 | 32.2 | |
| Interest income | | | | 40.3 | 0.0 | 32.7 | 32.2 | 0.0 |
| Other income (expense), net [+] | -30.4 | 7.9 | 10.5 | -69.7 | -1.7 | -44.3 | -38.9 | 43.1 |
| Gain (loss) on debt retirement | 2.6 | | | 15.9 | | | | |
| Gain (loss) on foreign currency transactions | -0.3 | 3.3 | 1.5 | -0.6 | | 1.1 | -4.0 | |
| Change in fair value of warrants | 13.4 | -19.6 | -19.9 | | 1.7 | | | -43.1 |
| Other | -0.2 | | | -1.6 | | 0.5 | 0.2 | |
| Pre-tax income | -44.0 | -66.7 | -23.1 | -111.3 | -1.2 | -39.6 | -47.8 | -45.1 |
| Income taxes | -1.1 | -7.4 | -4.1 | -5.6 | -0.1 | 14.4 | -7.1 | -0.2 |
| Tax rate | 2.5% | 11.1% | 17.7% | 5.0% | 12.0% | | 14.9% | 0.4% |
| Minority interest | -1.0 | -0.7 | -1.3 | | | -0.1 | | |
| Net income | -41.9 | -58.6 | -17.7 | -105.7 | -1.0 | -53.9 | -40.7 | -45.0 |
| Net margin | -23.0% | -33.3% | -10.8% | -62.9% | | -29.9% | -24.5% | |
| |
| Basic EPS [+] | ($0.22) | ($0.32) | ($0.10) | ($15.81) | ($0.01) | ($8.14) | ($6.18) | ($0.79) |
| Growth | 128.0% | -96.0% | -98.4% | | -96.8% | 352995.7% | | 4655543.3% |
| Diluted EPS [+] | ($0.22) | ($0.32) | ($0.10) | ($15.81) | ($0.01) | ($8.14) | ($6.18) | ($0.79) |
| Growth | 128.0% | -96.0% | -98.4% | | -96.8% | 352995.7% | | 4655543.3% |
| |
| Shares outstanding (basic) [+] | 187.7 | 181.0 | 180.8 | 6.7 | 93.8 | 6.6 | 6.6 | 57.0 |
| Growth | 3.8% | 2633.6% | 2644.8% | | 1.0% | -67.1% | -67.3% | 183.2% |
| Shares outstanding (diluted) [+] | 187.7 | 181.0 | 180.8 | 6.7 | 93.8 | 6.6 | 6.6 | 57.0 |
| Growth | 3.8% | 2633.6% | 2644.8% | | 1.0% | -67.1% | -67.3% | 183.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|